March 2009 Br J Cardiol 2009;16:60–2
Rebecca Kristeleit, Mary O’Brien
Cardiotoxicity and adjuvant anthracycline in early breast cancer Anthracycline-based polychemotherapy regimens for early-stage breast cancer have demonstrated a superior disease-free and overall survival in comparison to non-anthracycline based regimens.6 The increasing usage and efficacy of adjuvant chemotherapy is a significant factor contributing to the fall in mortality from breast cancer.6-9 However, the rising numbers of patients treated with anthracyclines in the adjuvant setting could mean that many women have sustained subclinical cardiac damage that is not yet clinically apparent. A recent analysis has attempted to define the exten
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits